Aerovate Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep '23 Sep 30, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Revenue	7.06	12.49	12.88	12.66	12.5
Revenue Growth (YoY)	-43.04%	-3.05%	1.79%	1.25%	-
Cost of Revenue	5.28	13.43	17.56	18.1	16.41
Gross Profit	1.77	-0.94	-4.68	-5.44	-3.91
Selling, General & Admin	7.45	8.94	12.32	4.77	3.74
Research & Development	-	-	-	1.74	0.48
Operating Expenses	9.63	10.91	14.21	7.11	4.79
Operating Income	-7.85	-11.85	-18.89	-12.55	-8.7
Interest Expense	-5.72	-3.73	-1.38	-0.47	-0.82
Other Non Operating Income (Expenses)	-5.74	-1.02	2.95	0.17	-0.04
EBT Excluding Unusual Items	-19.31	-16.6	-17.31	-12.86	-9.56
Impairment of Goodwill	-	-	-3.06	-	-
Gain (Loss) on Sale of Investments	-	-	1.17	-1.28	-
Gain (Loss) on Sale of Assets	0.13	0.23	-	-	-
Asset Writedown	-	-	-4.4	-	-
Legal Settlements	-	-	-	-0.75	-
Other Unusual Items	2.95	1.9	1.62	-	-
Pretax Income	-16.94	-14.46	-21.98	-14.89	-9.56
Earnings From Continuing Operations	-16.94	-14.46	-21.98	-14.89	-9.56
Earnings From Discontinued Operations	-0.41	-	2.47	1.12	1.78
Net Income to Company	-17.35	-14.46	-19.51	-13.78	-7.78
Minority Interest in Earnings	2.07	0.15	-0.18	1.99	0.61
Net Income	-15.28	-14.31	-19.69	-11.78	-7.16
Preferred Dividends & Other Adjustments	6.68	6.62	5.89	10.94	10.98
Net Income to Common	-21.95	-20.93	-25.57	-22.72	-18.15
Shares Outstanding (Basic)	24	18	14	12	1
Shares Outstanding (Diluted)	24	18	14	12	1
Shares Change (YoY)	42.34%	26.95%	11.46%	1634.85%	-
EPS (Basic)	-0.93	-1.20	-1.85	-1.84	-25.44
EPS (Diluted)	-0.93	-1.20	-1.85	-1.84	-25.44
Free Cash Flow	-4.84	-4.01	-2.85	-10.01	-9.89
Free Cash Flow Per Share	-0.20	-0.23	-0.21	-0.81	-13.87
Gross Margin	25.14%	-7.52%	-36.30%	-43.02%	-31.28%
Operating Margin	-111.29%	-94.91%	-146.62%	-99.19%	-69.61%
Profit Margin	-311.07%	-167.58%	-198.53%	-179.56%	-145.17%
Free Cash Flow Margin	-68.53%	-32.08%	-22.13%	-79.08%	-79.12%
EBITDA	-7.15	-11.35	-18.36	-11.95	-8.12
EBITDA Margin	-101.28%	-90.89%	-142.50%	-94.44%	-65.00%
D&A For EBITDA	0.71	0.5	0.53	0.6	0.58
EBIT	-7.85	-11.85	-18.89	-12.55	-8.7
EBIT Margin	-111.29%	-94.91%	-146.62%	-99.19%	-69.61%
Revenue as Reported	7.54	12.49	12.88	12.66	12.5

Updated Jan 16, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.